Meniere Disease – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Meniere Disease – Pipeline Review, H2 2017’, provides an overview of the Meniere Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Meniere Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Meniere Disease

The report reviews pipeline therapeutics for Meniere Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Meniere Disease therapeutics and enlists all their major and minor projects

The report assesses Meniere Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Meniere Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Meniere Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Meniere Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Orbis Biosciences Inc

Otonomy Inc

Quark Pharmaceuticals Inc

Sound Pharmaceuticals Inc

Synphora AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Meniere Disease - Overview

Meniere Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Meniere Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Meniere Disease - Companies Involved in Therapeutics Development

Orbis Biosciences Inc

Otonomy Inc

Quark Pharmaceuticals Inc

Sound Pharmaceuticals Inc

Synphora AB

Meniere Disease - Drug Profiles

betahistine dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

betamethasone valerate ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone acetate SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ebselen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OR-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPHL-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Meniere Disease - Dormant Projects

Meniere Disease - Product Development Milestones

Featured News & Press Releases

Jun 20, 2017: Otonomy to Host Key Opinion Leader Meeting for Investors on Meniere Disease

Feb 03, 2017: Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere Disease and Vestibular Vertigo

Jan 19, 2017: Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss

Aug 01, 2016: Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Meniere Disease Patients

Mar 23, 2016: Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Meniere Disease

Jan 26, 2016: Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss

Nov 18, 2015: Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere Disease

Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting

Sep 09, 2015: Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere Disease

May 21, 2015: Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere Disease

Apr 20, 2015: Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere Disease Patients

Dec 01, 2014: Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere Disease

Oct 09, 2014: Otonomy Enrolls First Meniere Disease Patients in OTO-104 Multiple-Dose Safety Study

Dec 11, 2013: Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere Disease

Sep 29, 2011: Otonomy Presents Positive New Findings From Phase Ib Study Of OTO-104 In Meniere Disease At International Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Meniere Disease, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Meniere Disease – Pipeline by Orbis Biosciences Inc, H2 2017

Meniere Disease – Pipeline by Otonomy Inc, H2 2017

Meniere Disease – Pipeline by Quark Pharmaceuticals Inc, H2 2017

Meniere Disease – Pipeline by Sound Pharmaceuticals Inc, H2 2017

Meniere Disease – Pipeline by Synphora AB, H2 2017

Meniere Disease – Dormant Projects, H2 2017

List of Figures

List of Figures

Number of Products under Development for Meniere Disease, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports